These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26549802)

  • 1. Validation of modeled pharmacoeconomic claims in formulary submissions.
    Langley PC
    J Med Econ; 2015; 18(12):993-9. PubMed ID: 26549802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating pharmaceutical product claims: questions a formulary committee should ask.
    Schommer JC; Carlson AM; Rhee TG
    J Med Econ; 2015; 18(12):1000-6. PubMed ID: 26548326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The status of modeled claims.
    Langley PC
    J Med Econ; 2015; 18(12):991-2. PubMed ID: 26549706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using 'big data' to validate claims made in the pharmaceutical approval process.
    Wasser T; Haynes K; Barron J; Cziraky M
    J Med Econ; 2015; 18(12):1013-9. PubMed ID: 26548546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive validation of modeled health technology assessment claims: lessons from NICE.
    Belsey J
    J Med Econ; 2015; 18(12):1007-12. PubMed ID: 26548424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When is a cost-effectiveness claim valid? How much should the FDA care?
    Luce BR; Hillman AL
    Am J Manag Care; 1997 Nov; 3(11):1660-6. PubMed ID: 10178464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science.
    Langley PC
    Curr Med Res Opin; 2016 Oct; 32(10):1641-1644. PubMed ID: 27181031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling for health care and other policy decisions: uses, roles, and validity.
    Weinstein MC; Toy EL; Sandberg EA; Neumann PJ; Evans JS; Kuntz KM; Graham JD; Hammitt JK
    Value Health; 2001; 4(5):348-61. PubMed ID: 11705125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.